{"id":"standard-duration-varenicline","safety":{"commonSideEffects":[{"rate":"30","effect":"Nausea"},{"rate":"21","effect":"Insomnia"},{"rate":"13","effect":"Abnormal dreams"},{"rate":"13","effect":"Headache"},{"rate":"10","effect":"Dizziness"},{"rate":"8","effect":"Constipation"}]},"_chembl":{"chemblId":"CHEMBL1076903","moleculeType":"Small molecule","molecularWeight":"211.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Varenicline binds with high affinity and selectivity to the alpha-4 beta-2 nicotinic receptor in the brain. As a partial agonist, it provides modest dopamine release to reduce withdrawal symptoms while simultaneously blocking nicotine from binding to the same receptor, preventing the reinforcing effects of smoking. This dual action makes it effective for smoking cessation.","oneSentence":"Varenicline is a partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor that reduces nicotine cravings and blocks the rewarding effects of nicotine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:01.274Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Smoking cessation"}]},"trialDetails":[{"nctId":"NCT04798664","phase":"NA","title":"Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-05-17","conditions":"Smoking Cessation","enrollment":3228},{"nctId":"NCT04525755","phase":"PHASE1, PHASE2","title":"STARS (Smoking Treatment And Remote Sampling) Study","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2021-02-08","conditions":"Smoking, Smoking Cessation, Tobacco Smoking","enrollment":652},{"nctId":"NCT04199117","phase":"PHASE4","title":"Health Systems Reach Interventions Project","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2020-03-11","conditions":"Smoking, Cigarette, Smoking Cessation","enrollment":210},{"nctId":"NCT06798324","phase":"PHASE4","title":"tDCS Plus Varenicline for Smoking Cessation","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2025-03-10","conditions":"Nicotine Dependence, Tobacco Smoking, Smoking Cessation","enrollment":160},{"nctId":"NCT04188873","phase":"PHASE4","title":"Cessation Screening Project","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2020-12-10","conditions":"Nicotine Dependence","enrollment":529},{"nctId":"NCT04738643","phase":"NA","title":"Improving Tobacco Treatment Rates for Cancer Patients Who Smoke","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2022-06-28","conditions":"Cancer, Tobacco Use, Smoking","enrollment":685},{"nctId":"NCT03365362","phase":"PHASE4","title":"A Trial of Directly Observed and Long-term Varenicline","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2018-10-25","conditions":"Tobacco Use Disorder, Opioid-use Disorder","enrollment":243},{"nctId":"NCT03176784","phase":"PHASE4","title":"UW Quitting Using Intensive Treatment Study (QUITS)","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-11-11","conditions":"Tobacco Dependence","enrollment":1251},{"nctId":"NCT01162239","phase":"PHASE3","title":"Maintaining Nonsmoking","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-05","conditions":"Nicotine Dependence","enrollment":216},{"nctId":"NCT02991781","phase":"NA","title":"Combined Bio- and Neuro- Feedback vs. Varenicline Use for Smoking Cessation","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2017-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD), Asthma, Smoking","enrollment":106},{"nctId":"NCT02941718","phase":"PHASE3","title":"Examination of Sleep, Smoking Cessation, and Cardiovascular Health","status":"COMPLETED","sponsor":"University of Delaware","startDate":"2016-11-01","conditions":"Nicotine Dependence","enrollment":30},{"nctId":"NCT01756885","phase":"PHASE3","title":"Extended Varenicline Treatment for Smoking Among Cancer Patients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2013-01","conditions":"Nicotine Dependence","enrollment":207},{"nctId":"NCT03809897","phase":"PHASE4","title":"Varenicline for Smoking Cessation in Hospitalized Patients With Psychiatric Disorders","status":"WITHDRAWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2019-01","conditions":"Tobacco Use Cessation, Psychiatric Disorders","enrollment":""},{"nctId":"NCT01532232","phase":"","title":"Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-02","conditions":"Breast Cancer, Tobacco Dependence","enrollment":7},{"nctId":"NCT01156610","phase":"NA","title":"Tobacco Treatment Outreach to Reduce Disparities for Primary Care Populations","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-11","conditions":"Smoking, Smoking Cessation","enrollment":706}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":36,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Standard Duration Varenicline","genericName":"Standard Duration Varenicline","companyName":"University of Wisconsin, Madison","companyId":"university-of-wisconsin-madison","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Varenicline is a partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor that reduces nicotine cravings and blocks the rewarding effects of nicotine. Used for Smoking cessation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}